NICE rejects J&J’s Darzalex regimen for multiple myelomaNew guidance from NICE has rejected a combination regimen based on Johnson & Johnson’s Darzalex for a group Share XNICE rejects J&J’s Darzalex regimen for multiple myelomahttps://pharmaphorum.com/news/nice-rejects-jj-darzalex-regimen-for-multiple-myeloma/
Jan van de Winkel: Building Europe’s biotech powerhouse at GenmabJan van de Winkel has overseen one of biotech’s big success stories since he took over Genmab’s CEO Share XJan van de Winkel: Building Europe’s biotech powerhouse at Genmabhttps://pharmaphorum.com/views-and-analysis/jan-van-de-winkel-building-europes-biotech-powerhouse-at-genmab/
Scotland backs Roche’s Rozlytrek for ROS1 lung cancerThe Scottish Medicines Consortium (SMC) has given a green light to Roche’s Rozlytrek for a rare form of Share XScotland backs Roche’s Rozlytrek for ROS1 lung cancerhttps://pharmaphorum.com/news/scotland-backs-roches-rozlytrek-for-ntrk-tumours/
Janssen combines Darzalex with COVID-19 drug in new multiple myeloma submissionJanssen has submitted a new combination regimen for its blockbuster multiple myeloma drug Darzalex for approval with the Share XJanssen combines Darzalex with COVID-19 drug in new multiple myeloma submissionhttps://pharmaphorum.com/news/janssen-combines-darzalex-with-covid-drug-in-new-multiple-myeloma-submission/
Sanofi builds case for Sarclisa, challenging J&J’s DarzalexSanofi is trumpeting new data for its anti-CD38 drug Sarclisa as it tries to capture market share from Share XSanofi builds case for Sarclisa, challenging J&J’s Darzalexhttps://pharmaphorum.com/news/sanofi-builds-case-for-sarclisa-challenging-jjs-darzalex/
J&J defends Darzalex with FDA approval for faster dosingJohnson & Johnson has claimed FDA approval for new formulation of its blockbuster multiple myeloma drug Darzalex that Share XJ&J defends Darzalex with FDA approval for faster dosinghttps://pharmaphorum.com/news/jj-defends-darzalex-with-fda-approval-for-faster-dosing/
Sanofi gets first OK for isatuximab for myeloma, challenging J&J’s DarzalexSanofi has claimed FDA approval for its anti-CD38 drug isatuximab as a third-line treatment for multiple myeloma, becoming Share XSanofi gets first OK for isatuximab for myeloma, challenging J&J’s Darzalexhttps://pharmaphorum.com/news/sanofi-gets-first-ok-for-isatuximab-for-myeloma-challenging-jjs-darzalex/
J&J gets okay for a third first-line Darzalex combo in USJohnson & Johnson continues to extend the use of its Darzalex therapy in newly-diagnosed multiple myeloma patients, getting Share XJ&J gets okay for a third first-line Darzalex combo in UShttps://pharmaphorum.com/news/jj-gets-okay-for-a-third-first-line-darzalex-combo-in-us/
NICE backs interim funding for J&J/Takeda myeloma regimenA three-drug regimen for multiple myeloma based on Johnson & Johnson’s Darzalex, Takeda’s Velcade and dexamethasone will be Share XNICE backs interim funding for J&J/Takeda myeloma regimenhttps://pharmaphorum.com/news/nice-backs-interim-funding-for-jj-takeda-myeloma-regimen/
